Patient

Global Market for Medical Devices 12th Edition Report: Featuring 3M, Abbott Laboratories, Alcon, Asahi Kasei and Baxter International Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, January 13, 2023
Medical Devices, Health, Positive economics, LaTeX, Laika (EHR testing framework), Electronic health record, Organization, Diagnosis, Growth, Patient, Metabolism, Research, Medical device, Investment, Pharmaceutical industry

The "The Global Market for Medical Devices, 12th Edition" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Global Market for Medical Devices, 12th Edition" report has been added to ResearchAndMarkets.com's offering.
  • The medical device industry is constantly updating and changing through the continued development of new technologies, equipment, tests and devices.
  • Advancements in the medical device markets are life-changing and are allowing patients to live longer, healthier and more productive lives.
  • The 12th edition of the Global Market for Medical Devices consists of new market trends and forecasts.

Disposable Medical Sensors Market Report 2022: Various Applications Of Biosensors In Medical Fields Bolster Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, January 13, 2023
Medical Devices, Health, Nano, Hospital, Biosensor, COVID-19, Defense, Bioreactor, FDA, Conditional sentence, SkyWater Technology, Growth, Food, Patient, Prevalence, DASA, Cancer, Diagnosis, Stroke, Food and Drug Administration, USD, Medical imaging, Pharmaceutical industry

The "Disposable Medical Sensors Market Size, Share & Trends Analysis Report By Application (Diagnostic, Therapeutic, Patient Monitoring), By Product (Biosensors, Pressure Sensors), By Type, By Region, And Segment Forecasts, 2023-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Disposable Medical Sensors Market Size, Share & Trends Analysis Report By Application (Diagnostic, Therapeutic, Patient Monitoring), By Product (Biosensors, Pressure Sensors), By Type, By Region, And Segment Forecasts, 2023-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global disposable medical sensors market size is anticipated to reach USD 36.24 billion by 2030, growing at a CAGR of 18.45% during the forecast period.
  • This will lead to the high adoption of disposable medical sensors because they are affordable and time-saving, thus driving market growth.
  • Additionally, due to disposable medical sensors advancing technological capabilities, the market expansion is projected to be fueled by rising demand for biosensors in bioreactors and drug research.

Mobile Cardiac Telemetry Systems Global Market Report 2023: Rising Prevalence of Cardiovascular Illness Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, January 13, 2023
Biotechnology, Health, Medical Devices, Hospital, COVID-19, Growth, Region, Application, Patient, Prevalence, Workforce, Mortality, Degenerative disease, USD, Arrhythmia, Medical device, Health insurance

The "Mobile Cardiac Telemetry Systems Market by Application, by End-user, and by Region - Global Forecast to 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Mobile Cardiac Telemetry Systems Market by Application, by End-user, and by Region - Global Forecast to 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The mobile cardiac telemetry systems market size is estimated to be USD 947.6 million in 2022 and is expected to witness a CAGR of 14.71% during the forecast period 2023-2033.
  • The rising prevalence of cardiovascular illnesses and their accompanying mortality, the rise in the frequency of arrhythmia, and the gadget is also useful for detecting arrhythmogenic concerns in COVID-19 patients in the outpatient scenario are factors contributing to the market growth.
  • In 2022, North America region accounted for the highest revenue in the mobile cardiac telemetry systems market and is expected to maintain its dominance during the forecast period.

The Worldwide Wound Dressing Industry is Expected to Reach $18.8 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 13, 2023
Medical Supplies, Health, Accident, Ageing, Hospital, COVID-19, International Diabetes Federation, Ulcer, WHO, Burn, Death, Burns, Growth, Gunshot, Patient, NCBI, Diabetes, Incidence, Pharmaceutical industry

Similarly, according to NCBI, the incidence rate of diabetes foot ulcers globally is between 9.1 million to 26.1 million annually.

Key Points: 
  • Similarly, according to NCBI, the incidence rate of diabetes foot ulcers globally is between 9.1 million to 26.1 million annually.
  • Thus, the rise in diabetes and diabetic foot ulcer patients is increasing the demand for wound dressing products, thereby impelling the market over the forecast period.
  • Whereas, the home healthcare segment is expected to witness the fastest growth rate of 5.9% over the forecast period.
  • This can be attributed to the rising geriatric population and the increase in the number of people suffering from diabetes
    Chapter 3 Wound Dressing Market Variables, Trends & Scope

Global Refurbished Medical Equipment Market Report 2022 to 2027: High Capital & Procurement Costs of Medical Equipment Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, January 13, 2023
Hospitals, Health, Medical Supplies, Medical Devices, City, Hospital, Employment, ROI, Monkeypox, Patient, Small, Prevalence, Bed, Life, Learning curve, COVID-19, Medical device, Real estate, Mobile phone

The global refurbished medical equipment market is expected to grow at a CAGR of 11.76% during 2022-2027.

Key Points: 
  • The global refurbished medical equipment market is expected to grow at a CAGR of 11.76% during 2022-2027.
  • The global refurbished medical equipment market grew significantly during the pre-pandemic times.
  • Nearly one-third of the medical equipment industry in developing countries is part of the refurbished medical equipment market.
  • The global refurbished medical equipment market eliminates the annoying problems faced in using a worn-down machine and avoids the learning curve associated with new equipment.

Dawn Health Expands Insomnia Treatment Access with Insurance Coverage in Texas

Retrieved on: 
Friday, January 13, 2023
Professional Services, Mental Health, Health, Telemedicine, Virtual Medicine, Insurance, Other Health, Health Insurance, Memory, Cognitive behavioral therapy, Sleep disorder, Quality of life, Sleep, Dawn, Rest, Patient, Cognitive behavioral therapy for insomnia, Health insurance, Insomnia, Twilio, Segment

Today, Dawn Health, the leading provider of Insomnia Treatment, announces it is accepting insurance for patients in Texas, expanding access to Insomnia Therapy for approximately 10 million more people.

Key Points: 
  • Today, Dawn Health, the leading provider of Insomnia Treatment, announces it is accepting insurance for patients in Texas, expanding access to Insomnia Therapy for approximately 10 million more people.
  • Dawn is making Cognitive Behavioral Therapy for Insomnia (CBT-I), the gold-standard treatment for Insomnia, more accessible, effective, and affordable.
  • This will provide you with a list of the insurance plans that will likely be accepted by Dawn Health in your state.
  • Drawing inspiration from his own experience, Dawn Health Co-Founder Rahul Shivkumar says, "Our mission at Dawn is to build the new standard of care for Insomnia treatment."

Nerviano Medical Sciences Strengthens Executive Team to Maximize IDH1/IDH2 Inhibitor Asset

Retrieved on: 
Friday, January 13, 2023
Research, Clinical Trials, Biotechnology, Biometrics, Health, Pharmaceutical, Other Science, Science, Oncology, University, Merck, Therapy, Merck Group, AML, Virtual, IPO, FDA, S.P. Bansal, NMS, Medicine, IDH2, BS, Merck Serono, Patient, Cholangiocarcinoma, Pharming, IDH1, Program management, Bicycle, MBA, University of Phoenix, Doctor of Philosophy, Pharmaceutical industry, Exelixis, New business development, Chemistry

Mr. West is a seasoned biopharma executive with over 25 years of experience in all levels of both public and private organizations leading and managing pipeline development across multiple therapeutic areas.

Key Points: 
  • Mr. West is a seasoned biopharma executive with over 25 years of experience in all levels of both public and private organizations leading and managing pipeline development across multiple therapeutic areas.
  • “With the addition of Terrence to the executive team, we are beginning to really establish our footprint in the Boston area,” stated Lisa Mahnke, M.D., PhD, Board Member and Chief Medical Officer of NMS S.r.l.
  • He previously served as Executive Director, Program Management at EMD Serono (a division of Merck KGaA), leading the development, global registration and commercialization of multiple oncology drugs.
  • Mr. West holds a MBA from the University of Phoenix, San Francisco and a BS in Chemistry from the University of Arizona.

Appili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole

Retrieved on: 
Friday, January 13, 2023
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Infection, Therapy, Patent, TSX, FDA, Metronidazole, Drug development, Patient, Prescription, Pharming, Recurrence, Pharmaceutical industry

Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance of new patent claims for ATI-1501 , Appili’s liquid oral reformulation of the antibiotic metronidazole.

Key Points: 
  • Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance of new patent claims for ATI-1501 , Appili’s liquid oral reformulation of the antibiotic metronidazole.
  • A notice of allowance is issued by the USPTO to indicate that the application has passed the examination.
  • Metronidazole is a widely used frontline oral treatment with over 10 million prescriptions written in the United States every year to help treat parasitic and anaerobic bacterial infections.
  • “We are pleased with this notice of allowance for a new patent that will further strengthen ATI-1501’s potential as a more convenient antibiotic treatment option,” said Don Cilla, Pharm.D., M.B.A., President and Chief Executive Officer of Appili Therapeutics.

AHF Eswatini Commemorates 15th Year with New Centre of Excellence!

Retrieved on: 
Friday, January 13, 2023
Oncology, AIDS, Philanthropy, Health, Foundation, General Health, Pharmaceutical, Local-level governments of Papua New Guinea, AIDS Healthcare Foundation, TB, Population Services International, Entrepreneurship, Education, AIDS, HIV, Matsapha, Medicine, Government, Ministry, Center of excellence, Cervical cancer, Kingdom, Georgetown University, MOH, FLAS, Partnership, Pharmacy, Woman, Growth, Patient, HIV/AIDS, AHF, Ministry of Health (Saudi Arabia), SZL, PSI, Member, ART, Multimedia, Watts Labor Community Action Committee, Pharmaceutical industry, Medical device

View the full release here: https://www.businesswire.com/news/home/20230112005861/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230112005861/en/
    As part of its commemoration of 15 years in the country, AHF Eswatini will unveil its newly constructed state-of-the-art LaMvelase Centre of Excellence in partnership with the Manzini City Council on Jan. 13.
  • (Photo: Business Wire)
    As part of its commemoration, AHF Eswatini will unveil its newly constructed state-of-the-art LaMvelase Centre of Excellence in partnership with the Manzini City Council (who provided the land on which the clinic sits).
  • Although providing treatment was AHF Eswatini’s foremost priority, it has attained much more in over a decade.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare .

Viz.ai Launches AI-Powered Viz™ Vascular Suite

Retrieved on: 
Thursday, January 12, 2023
Health, Technology, Hospitals, Health Technology, Software, Artificial Intelligence, Cardiology, AAA, Communication, Pathology, Pulmonary embolism, FDA, MD, AI, CT, ECG, Viz, Patient, Intelligence, Degenerative disease, Multimedia, Health, Triage, Medical device, Medical imaging

View the full release here: https://www.businesswire.com/news/home/20230112005812/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230112005812/en/
    “Recognizing the symptoms of serious vascular conditions, such as aortic dissections, is hugely important because any delay in treatment can have a direct impact on patient outcomes,” said Philip Batista, MD, Associate Program Director, Vascular and Endovascular Surgery Residency, Cooper.
  • We’ve been using the Viz software for the last several months and have seen improvements in patient care across our institution.”
    The Viz Vascular Suite uses artificial intelligence to automatically analyze an array of imaging modalities, including computerized tomography (CT), electrocardiogram (ECG), and more for suspected vascular diseases.
  • Clinicians can use Viz Vascular Suite to remotely coordinate vascular pathology care within a hospital system’s hub and spoke network and enable synchronous, HIPAA-compliant communication among specialists.
  • The Viz Vascular Suite will bring the advantages of intelligent care coordination to even more patients and help clinical teams achieve better clinical outcomes,” said Chris Mansi, CEO of Viz.ai.